HOME >> MEDICINE >> NEWS
New alzheimer's drug shows promise in clinical trial

Washington, DC--The only drugs currently available for Alzheimer's patients are those that alleviate symptoms, but a team of scientists led by Paul Aisen, MD, director of the Memory Disorders program at Georgetown University Medical Center, is testing a new class of drugs that actually target the molecule believed to cause the disease. Aisen and his colleagues report that a compound called tramiprosate reduced levels of a marker for the progression of Alzheimer's disease in a Phase II clinical trial in the November 1 electronic version of Neurology.

"Everyone wants to figure out how to create an Alzheimer's treatment that attacks the amyloid peptide, which is considered to be the molecular cause of the disease," said Aisen. "This is the most advanced anti-amyloid treatment that exists--it has the potential for slowing down progression of the disease."

Aisen and his team are currently in the midst of Phase III clinical trials on tramiprosate (manufactured by Neurochem, for which Aisen is a scientific advisor, as ALZHEMEDTM) and hope to have results by early next summer. Media should call 202-687-5100 to schedule an interview with Aisen or to be connected with another Georgetown expert on the topic.


'"/>

Contact: Becky Wexler
rjw43@georgetown.edu
202-687-5100
Georgetown University Medical Center
2-Nov-2006


Page: 1

Related medicine news :

1. New study shows promise in reducing surgical risks associated with surgical bleeding
2. Most seniors now have drug coverage, U-M study shows
3. Wireless technology shows promise in diagnosing pediatric intestinal disease
4. Study shows radiofrequency ablation highly effective in treating kidney tumors
5. Method shows promise for early detection of pancreatic cancer
6. Organic farming can feed the world, U-M study shows
7. New study shows Rescue Remedy is an effective all-natural stress, anxiety reliever
8. Borderline personality disorder shows improvements with intensive psychotherapy
9. New drug shows promise in treatment of advanced thyroid cancer
10. Study shows Diachrome improves blood sugar control in people with type 2 diabetes
11. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/9/2018)... COSTA MESA, Calif. (PRWEB) , ... August 09, ... ... treatment, officially announces LegitScript certification. LegitScript is a new verification process that substance ... Longridge said, “Being LegitScript certified means we can reach more people to help.” ...
(Date:8/9/2018)... ... August 09, 2018 , ... Thanks to the ... company’s independent distributors, customers, and employees, the newly established Isagenix Legacy Foundation ... $2 million goal. 100 percent of the donations will fund grants to nonprofit ...
(Date:8/7/2018)... ... 07, 2018 , ... Today Springfield Creamery added six new ... cream-on-top-style yogurts are made with milk from grass-fed cows who enjoy a diet ... acids. Nancy’s sources the milk from organic family-owned farms, all within 60 miles ...
(Date:8/3/2018)... ... ... On August 2, 2018 the JPML ordered that the Zostavax MDL be ... has been litigating Zostavax injuries since 2011. , On ... the thousands of people injured by Zostavax, a vaccine given to adults to prevent ...
(Date:8/2/2018)... ... 02, 2018 , ... Dr. Srini Pillay , best-selling author of ... people could care less, demonstrating a “whatever” attitude toward life, people, and situations around ... one often overlooked reason relates to being overworked. Called self-regulation depletion (SRD), this condition ...
Breaking Medicine News(10 mins):
(Date:8/9/2018)... (PRWEB) , ... August 09, 2018 , ... ... CBD Day with Charlotte-area company cbdMD named the exclusive sponsor. , “We’re honored ... exciting to see such public embrace for CBD on a national level,” said ...
(Date:8/7/2018)... ... August 07, 2018 , ... Commissioner Gottlieb’s FDA:, Analysis of First ... – 3:00 p.m. ET, http://www.fdanews.com/commissionergottliebsfda , Under Commissioner Scott Gottlieb, changes ... have benefited, some may have gotten hurt. , And Gottlieb is just getting started. ...
(Date:8/7/2018)... PLEASANTON, Calif. (PRWEB) , ... ... ... Chief Executive Officer, today announced the appointment of Richard A. Stark to assume the role of Sanarus ... will apply his 20+ years of strategic development, marketing and sales experience in medical ...
Breaking Medicine Technology:
Cached News: